PE20170086A1 - Derivados de naftiridinadiona - Google Patents
Derivados de naftiridinadionaInfo
- Publication number
- PE20170086A1 PE20170086A1 PE2016002514A PE2016002514A PE20170086A1 PE 20170086 A1 PE20170086 A1 PE 20170086A1 PE 2016002514 A PE2016002514 A PE 2016002514A PE 2016002514 A PE2016002514 A PE 2016002514A PE 20170086 A1 PE20170086 A1 PE 20170086A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- hemophilia
- naphthyridine
- dione
- cyclobutyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 abstract 1
- BQIOQCJVWRCOGK-UHFFFAOYSA-N 1,8-naphthyridine-2,3-dione Chemical class C1=CC=NC2=NC(=O)C(=O)C=C21 BQIOQCJVWRCOGK-UHFFFAOYSA-N 0.000 abstract 1
- LXUGLGYBWTXONW-UHFFFAOYSA-N 3-cyclobutyl-2-phenyl-5H-benzo[b][1,6]naphthyridine-1,10-dione Chemical compound C1(CCC1)C=1N(C(C=2C(C3=C(NC2C1)C=CC=C3)=O)=O)C3=CC=CC=C3 LXUGLGYBWTXONW-UHFFFAOYSA-N 0.000 abstract 1
- CGZAGUMOJBOBDZ-UHFFFAOYSA-N 3-cyclobutyl-5-methyl-2-phenylbenzo[b][1,6]naphthyridine-1,10-dione Chemical compound C1(CCC1)C=1N(C(C=2C(C3=C(N(C2C1)C)C=CC=C3)=O)=O)C3=CC=CC=C3 CGZAGUMOJBOBDZ-UHFFFAOYSA-N 0.000 abstract 1
- 102100022641 Coagulation factor IX Human genes 0.000 abstract 1
- 102100026735 Coagulation factor VIII Human genes 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 201000003542 Factor VIII deficiency Diseases 0.000 abstract 1
- 208000009292 Hemophilia A Diseases 0.000 abstract 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract 1
- 108020004485 Nonsense Codon Proteins 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 208000009429 hemophilia B Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000006574 non-aromatic ring group Chemical group 0.000 abstract 1
- 230000037434 nonsense mutation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se refiere a derivados de naftiridinadiona de formula (I´) en forma libre o sal farmaceuticamente aceptable en donde: R1 es un anillo no aromatico monociclico de 5 a 7 miembros saturado o insaturado que puede contener de 1 a 4 heteroatomos seleccionados de N, O y S; R2 es alquilo C2-C6 opcionalmente sustituido, entre otras opciones; R3 es H o -CH2R18; R18 es H, alquilo C1-C4, entre otros; R4 y R5 son H, alquilo C1-C3 o R4 y R5 forman un anillo; R24 es H o halogeno. Son compuestos preferidos: 3-ciclobutil-2-fenil-benzo-[b][1,6]-naftiridina-1,10(2H,5H)-diona; 3-ciclobutil-5-metil-2-fenil-benzo-[b][1,6]-naftiridina-1,10(2H,5H)-diona; entre otros. Tambien se refiere a una composicion farmaceutica, una combinacion y un metodo. Dichos compuestos suprimen las mutaciones sin sentido siendo utiles en el tratamiento de hemofilia A, hemofilia B, fibrosis quistica, entre otros
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14170976 | 2014-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170086A1 true PE20170086A1 (es) | 2017-03-17 |
Family
ID=50841689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016002514A PE20170086A1 (es) | 2014-06-03 | 2015-06-02 | Derivados de naftiridinadiona |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US10138232B2 (es) |
| EP (1) | EP3152209B1 (es) |
| JP (2) | JP6343034B2 (es) |
| KR (1) | KR101905295B1 (es) |
| CN (1) | CN106459043B (es) |
| AP (1) | AP2016009545A0 (es) |
| AR (1) | AR100706A1 (es) |
| AU (2) | AU2015270125B2 (es) |
| BR (1) | BR112016027383A8 (es) |
| CA (1) | CA2950724A1 (es) |
| CL (1) | CL2016003081A1 (es) |
| CR (1) | CR20160565A (es) |
| CU (1) | CU24438B1 (es) |
| EA (1) | EA030374B1 (es) |
| EC (1) | ECSP16096831A (es) |
| ES (1) | ES2731802T3 (es) |
| GT (1) | GT201600252A (es) |
| IL (1) | IL248773B (es) |
| MX (1) | MX374245B (es) |
| MY (1) | MY178379A (es) |
| PE (1) | PE20170086A1 (es) |
| PH (2) | PH12016502293A1 (es) |
| SG (1) | SG11201609209YA (es) |
| SV (1) | SV2016005331A (es) |
| TN (1) | TN2016000490A1 (es) |
| TW (1) | TWI688565B (es) |
| UY (1) | UY36150A (es) |
| WO (1) | WO2015186063A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TN2016000490A1 (en) | 2014-06-03 | 2018-04-04 | Novartis Ag | Naphthyridinedione derivatives. |
| JP6560257B2 (ja) * | 2014-06-03 | 2019-08-14 | ノバルティス アーゲー | ピリミド［４，５−ｂ］キノリン−４，５（３Ｈ，１０Ｈ）−ジオン誘導体 |
| EP3152207B1 (en) | 2014-06-03 | 2019-05-08 | Novartis AG | Pyridopyrimidinedione derivatives as suppressors of non-sens mutations |
| WO2019225625A1 (ja) * | 2018-05-23 | 2019-11-28 | 京都薬品工業株式会社 | リードスルー誘導剤およびその医薬用途 |
| US20210273002A1 (en) | 2018-07-24 | 2021-09-02 | Sony Semiconductor Solutions Corporation | Semiconductor device |
| WO2024161623A1 (ja) * | 2023-02-03 | 2024-08-08 | 株式会社 RINAT Imaging | リードスルー薬、リードスルー用組み合わせ剤及び核酸プローブの使用 |
| CN117756607A (zh) * | 2023-12-01 | 2024-03-26 | 陕西煤业化工技术研究院有限责任公司 | 一种二甲酚馏分异构化生产高值二甲酚的工艺及系统 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2884170B2 (ja) | 1989-08-24 | 1999-04-19 | 株式会社フジモト・ブラザーズ | ５−デアザフラビン系化合物を有効成分とする制癌剤 |
| JP2989871B2 (ja) * | 1989-08-30 | 1999-12-13 | 大日本製薬株式会社 | 三環式化合物 |
| DE4035479A1 (de) | 1990-11-08 | 1992-05-14 | Basf Ag | Substituierte pyrido (2,3-d)pyrimidin-2,4(1h,3h)-dione |
| US5908930A (en) | 1995-03-15 | 1999-06-01 | Pfizer Inc. | 5,10-dihydropyrimdo 4,5-b!quinolin-4(1H)-one tyrosine kinase inhibitors |
| US6016875A (en) * | 1998-02-10 | 2000-01-25 | Case Corporation | Gain adaptation control for hydraulic systems |
| US6468990B1 (en) * | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| AU2003249244A1 (en) | 2002-07-15 | 2004-02-02 | Combinatorx, Incorporated | Methods for the treatment of neoplasms |
| ES2887054T3 (es) | 2003-04-11 | 2021-12-21 | Ptc Therapeutics Inc | Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| CN104788328B (zh) * | 2004-06-24 | 2017-09-12 | 沃泰克斯药物股份有限公司 | Atp‑结合弹夹转运蛋白的调控剂 |
| CN101076332A (zh) * | 2004-10-13 | 2007-11-21 | Ptc医疗公司 | 吡唑或三唑化合物及其用于制备治疗体细胞突变相关疾病的药物的用途 |
| DK2390255T3 (en) | 2006-04-03 | 2016-11-07 | Technion Res & Dev Foundation | Novel aminoglycosides and uses thereof in the treatment of genetic disorders |
| TW200819454A (en) | 2006-08-23 | 2008-05-01 | Neurogen Corp | Haloalkyl-substituted pyrimidinone derivatives |
| CA2688004C (en) * | 2007-05-25 | 2016-07-05 | Vertex Pharmaceuticals Incorporated | Thienopyridone compounds for use as modulators of cystic fibrosis transmembrane conductance regulator |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| EP2422817A1 (en) | 2010-07-29 | 2012-02-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Flavin-nucleic acid ligand conjugates |
| CN103189060A (zh) * | 2010-08-05 | 2013-07-03 | 里尔法律与医疗卫生第二大学 | 用于对无义突变介导的疾病进行治疗的化合物和含有所述化合物的药物组合物 |
| SG11201503684WA (en) | 2012-12-13 | 2015-06-29 | Novartis Ag | Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors |
| JP6560257B2 (ja) | 2014-06-03 | 2019-08-14 | ノバルティス アーゲー | ピリミド［４，５−ｂ］キノリン−４，５（３Ｈ，１０Ｈ）−ジオン誘導体 |
| TN2016000490A1 (en) | 2014-06-03 | 2018-04-04 | Novartis Ag | Naphthyridinedione derivatives. |
| EP3152207B1 (en) | 2014-06-03 | 2019-05-08 | Novartis AG | Pyridopyrimidinedione derivatives as suppressors of non-sens mutations |
-
2015
- 2015-06-02 TN TN2016000490A patent/TN2016000490A1/en unknown
- 2015-06-02 WO PCT/IB2015/054174 patent/WO2015186063A1/en not_active Ceased
- 2015-06-02 CN CN201580029417.3A patent/CN106459043B/zh not_active Expired - Fee Related
- 2015-06-02 JP JP2016570886A patent/JP6343034B2/ja not_active Expired - Fee Related
- 2015-06-02 KR KR1020167033550A patent/KR101905295B1/ko not_active Expired - Fee Related
- 2015-06-02 TW TW104117848A patent/TWI688565B/zh not_active IP Right Cessation
- 2015-06-02 CR CR20160565A patent/CR20160565A/es unknown
- 2015-06-02 AR ARP150101737A patent/AR100706A1/es unknown
- 2015-06-02 EP EP15731121.8A patent/EP3152209B1/en active Active
- 2015-06-02 AU AU2015270125A patent/AU2015270125B2/en not_active Ceased
- 2015-06-02 PE PE2016002514A patent/PE20170086A1/es unknown
- 2015-06-02 SG SG11201609209YA patent/SG11201609209YA/en unknown
- 2015-06-02 EA EA201692270A patent/EA030374B1/ru not_active IP Right Cessation
- 2015-06-02 MY MYPI2016704068A patent/MY178379A/en unknown
- 2015-06-02 BR BR112016027383A patent/BR112016027383A8/pt active Search and Examination
- 2015-06-02 US US14/728,613 patent/US10138232B2/en active Active
- 2015-06-02 CA CA2950724A patent/CA2950724A1/en not_active Abandoned
- 2015-06-02 ES ES15731121T patent/ES2731802T3/es active Active
- 2015-06-02 AP AP2016009545A patent/AP2016009545A0/en unknown
- 2015-06-02 CU CU2016000182A patent/CU24438B1/es unknown
- 2015-06-02 MX MX2016015856A patent/MX374245B/es active IP Right Grant
- 2015-06-03 UY UY0001036150A patent/UY36150A/es not_active Application Discontinuation
-
2016
- 2016-11-06 IL IL248773A patent/IL248773B/en active IP Right Grant
- 2016-11-17 PH PH12016502293A patent/PH12016502293A1/en unknown
- 2016-11-30 CL CL2016003081A patent/CL2016003081A1/es unknown
- 2016-12-02 GT GT201600252A patent/GT201600252A/es unknown
- 2016-12-02 SV SV2016005331A patent/SV2016005331A/es unknown
- 2016-12-28 EC ECIEPI201696831A patent/ECSP16096831A/es unknown
-
2018
- 2018-01-18 AU AU2018200421A patent/AU2018200421A1/en not_active Withdrawn
- 2018-05-17 JP JP2018095248A patent/JP2018138609A/ja active Pending
- 2018-08-13 PH PH12018501709A patent/PH12018501709A1/en unknown
- 2018-10-10 US US16/156,447 patent/US20190248784A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170086A1 (es) | Derivados de naftiridinadiona | |
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| MX2022012317A (es) | Oxisteroles y metodos de uso de los mismos. | |
| PE20161372A1 (es) | Inhibidores de dihidropirrolopiridina de ror-gamma | |
| PE20212077A1 (es) | Nuevos compuestos sulfonamida de carboxamida | |
| PE20181289A1 (es) | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa | |
| PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| PH12018500065A1 (en) | Oxysterols and methods of use thereof | |
| PE20191304A1 (es) | Modulador del regulador de conductancia de transmembrana de fibrosis quistica, composiciones farmaceuticas, metodos de tratamiento y proceso para producir el modulador | |
| NZ768373A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| PE20181269A1 (es) | Agonistas del receptor de apelina y metodos de uso | |
| DOP2016000298A (es) | Pirazolopiridinas y pirazolopirimidinas | |
| EA201791256A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| PE20161368A1 (es) | Inhibidores de diacilglicerol aciltranferasa 2 | |
| PE20161384A1 (es) | Ciclopropilaminas como inhibidores de lsd 1 | |
| PE20181074A1 (es) | Compuestos heteroaromaticos como inhibidores de btk | |
| EA201790024A1 (ru) | Модуляторы toll-подобных рецепторов для лечения вич | |
| PE20161225A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| PE20142098A1 (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
| PE20170323A1 (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| PE20151062A1 (es) | PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONAS COMO SUPRESORAS DE MUTACION SIN SENTIDO | |
| PE20161369A1 (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona sustituidos con tetrazolona |